Evolus, Inc. has grown revenue 23% a year over three years and 33% a year over five. Revenue growth, 3-year annual rate: +23% (Drug Manufacturers - Specialty & Generic median +13%). Revenue growth, 5-year rate: +33%, growth has slowed since the five-year average. Years of annual history on file: 9, FY2017 to FY2025, as filed.

EOLSEvolus, Inc.

Healthcare

$7.79+24% 1Y

$7.79

$3.9452 weeks$9.30

Is it growing?

Good

Growing: revenue growing +14% year on year and operating margin widening (+9.6 points).

2 good, 1 without data

Revenue trend+14% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +33% a year.

Margin direction+9.6 points operating

Trailing-twelve-month operating margin, -6.7% now against -16.3% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is EOLS growing?

Evolus, Inc. has grown revenue 23% a year over three years and 33% a year over five.

+23%

Revenue growth, 3-year annual rate · Drug Manufacturers - Specialty & Generic median +13% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +33%
Revenue growth, 5-year rate · +23% over three · growth has slowed since the five-year average
Years of annual history on file: 9
Years of annual history on file · FY2017 to FY2025, as filed

Details›